Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
European Journal of Radiology|July 29, 2011
Growth rate of lung cancer recognized as small solid nodule on initial CT findingsKei Mikita, Haruhiro Saito, Yuji Sakuma, et al.
Asia-Pacific Journal of Clinical Oncology|June 29, 2016
Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinomaTeppei Nishii, Tomoyuki Yokose, Yohei Miyagi, et al.
European Journal of Radiology|December 17, 2009
Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in sizeShuji Murakami, Haruhiro Saito, Yuji Sakuma, et al.
Frontiers in Immunology|October 20, 2025
Machine learning-based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitorsFeifei Wei, Hiroyuki Takeda, Koichi Azuma, et al.
International Journal of Cancer|October 12, 2018
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitorNorikazu Matsuo, Koichi Azuma, Satoshi Hattori, et al.
Cancer Medicine|December 15, 2020
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancerTsuneo Shimokawa, Kazuhiko Yamada, Hiroshi Tanaka, et al.
BMC Cancer|August 26, 2014
Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancerTeppei Nishii, Tomoyuki Yokose, Yohei Miyagi, et al.
Frontiers in Immunology|December 30, 2024
Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinomaHuihui Xiang, Rika Kasajima, Koichi Azuma, et al.
Cancer Medicine|May 25, 2023
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, et al.
Frontiers in Cell and Developmental Biology|March 12, 2024
Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitorsYoshiro Nakahara, Taku Kouro, Satoru Motoyama, et al.
Pageof 13